Published in Rev Urol on January 01, 2009
Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure? Int Urogynecol J (2011) 0.85
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Qual Life Res (2015) 0.84
Overactive bladder after female genital mutilation/cutting (FGM/C) type III. BMJ Case Rep (2013) 0.77
A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms. Nurs Res (2012) 0.77
European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder. Int Urogynecol J (2013) 0.75
Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med (1996) 12.47
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 9.92
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes (2004) 3.95
Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res (2002) 2.66
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm (2008) 2.45
Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology (2004) 2.22
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ (2006) 1.96
Patient-reported reasons for discontinuing overactive bladder medication. BJU Int (2009) 1.94
Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol (1993) 1.72
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract (2008) 1.68
Issues in the measurement of satisfaction with treatment. Am J Manag Care (1997) 1.67
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 1.62
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry (2007) 1.38
Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes (2004) 1.37
Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society. Neurourol Urodyn (1998) 1.34
Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care (2005) 1.34
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol (2002) 1.32
Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health (2005) 1.32
Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn (2008) 1.26
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther (2006) 1.23
Determining the importance of change in the overactive bladder questionnaire. J Urol (2006) 1.19
The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. Value Health (2005) 1.11
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol (2009) 1.11
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int (2006) 1.08
Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology (1996) 1.08
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int (2005) 1.06
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract (2009) 1.05
Assessment of satisfaction with treatment for chronic pain. J Pain Symptom Manage (1997) 1.03
Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology (2006) 1.01
Oxybutynin: is it safe? Br J Urol (1988) 0.92
Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int (2008) 0.90
Extended-release trospium chloride improves quality of life in overactive bladder. Value Health (2009) 0.90
The effects of reformulation: improved therapeutic index. Curr Urol Rep (2008) 0.88
Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int (1999) 0.85
Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care (2005) 0.84
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Urol (2009) 0.84
Treatment of urge incontinence in Veterans Affairs medical centers. Clin Ther (1999) 0.82
An equilibrium model of drug utilization. J Clin Epidemiol (1993) 0.82
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn (2008) 0.78
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Artificial urinary sphincter revision: the role of ultrasound. Urology (2013) 2.62
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
An artificial somatic-central nervous system-autonomic reflex pathway for controllable micturition after spinal cord injury: preliminary results in 15 patients. J Urol (2003) 1.73
Managing the urethra at transvaginal pelvic organ prolapse repair: a urodynamic approach. J Urol (2008) 1.67
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol (2005) 1.49
Artificial urinary sphincter versus male sling for post-prostatectomy incontinence--what do patients choose? J Urol (2009) 1.30
American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. Urology (2003) 1.30
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn (2013) 1.17
Comparison of diagnostic criteria for female bladder outlet obstruction. J Urol (2006) 1.14
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc (2008) 1.11
Review article: Mid-urethral synthetic slings for female stress urinary incontinence. BJU Int (2010) 1.10
Female urethral reconstruction. Urol Clin North Am (2011) 1.01
Female stress urinary incontinence: how do patient and physician perspectives correlate in assessment of outcomes? Curr Opin Urol (2006) 0.99
The male perineal sling: assessment and prediction of outcome. J Urol (2007) 0.95
Surgical management of Skene's gland abscess/infection: a contemporary series. Int Urogynecol J (2011) 0.95
Effect of tension-free vaginal tape and TVT-obturator on lower urinary tract symptoms other than stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.94
A urodynamics protocol to optimally assess men with post-prostatectomy incontinence. Neurourol Urodyn (2005) 0.90
Primary bladder neck obstruction in men and women. Rev Urol (2005) 0.90
Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol (2006) 0.90
Urinary incontinence. Prim Care (2010) 0.88
Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology (2002) 0.87
Treatment of post-prostatectomy incontinence with male slings in patients with impaired detrusor contractility on urodynamics and/or who perform Valsalva voiding. J Urol (2011) 0.87
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J (2014) 0.87
Patient perception of videourodynamic testing: a questionnaire based study. J Urol (2005) 0.86
Clinical impact of overactive bladder. Rev Urol (2002) 0.85
Midurethral slings for all stress incontinence: a urology perspective. Urol Clin North Am (2012) 0.85
Management of recurrent urinary tract infections in healthy adult women. Rev Urol (2013) 0.84
Repeat urethrolysis after failed urethrolysis for iatrogenic obstruction. J Urol (2003) 0.84
Management of obstructive voiding dysfunction after incontinence surgery: lessons learned. Urology (2003) 0.83
Degree of bother caused by nocturia in women. Neurourol Urodyn (2004) 0.83
Outcomes of patients lost to followup after mid urethral synthetic slings--successes or failures? J Urol (2010) 0.81
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.81
Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int (2005) 0.81
Urodynamic differences between dysfunctional voiding and primary bladder neck obstruction in women. Urology (2012) 0.80
Recent advances in management of female lower urinary tract trauma. Curr Opin Urol (2003) 0.80
Primary bladder neck obstruction in men, women, and children. Curr Urol Rep (2007) 0.80
Duloxetine: a new pharmacologic therapy for stress urinary incontinence. Rev Urol (2004) 0.79
Voiding dysfunction in young, nulliparous women: symptoms and urodynamic findings. Int Urogynecol J Pelvic Floor Dysfunct (2004) 0.78
Long-term continence after surgery--what can we tell patients? J Urol (2012) 0.78
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology (2008) 0.78
Diagnosis and treatment of primary bladder neck obstruction in men. Curr Urol Rep (2005) 0.77
Comparison of urodynamic findings in women with anatomical versus functional bladder outlet obstruction. Female Pelvic Med Reconstr Surg (2013) 0.77
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J Urol (2014) 0.77
Can noninvasive evaluation of benign prostatic obstruction be optimized? Curr Opin Urol (2012) 0.77
Correlation of abdominal leak point pressure with objective incontinence severity in men with post-radical prostatectomy stress incontinence. Neurourol Urodyn (2005) 0.76
Tolterodine for treatment of overactive bladder. Urol Clin North Am (2006) 0.76
Endoscopic evacuation of Durasphere. Urology (2003) 0.76
Transdermal therapy for overactive bladder: present and future. Rev Urol (2003) 0.75
Reply: To PMID 24295256. Urology (2013) 0.75
Urodynamics for clinically suspected obstruction after anti-incontinence surgery in women. J Urol (2013) 0.75
Editorial comment. Urology (2011) 0.75
Editorial comment. Urology (2011) 0.75
Is There a Role for alpha-Blockers for the Treatment of Voiding Dysfunction Unrelated to Benign Prostatic Hyperplasia? Rev Urol (2005) 0.75
Association between detrusor overactivity and postoperative outcomes in patients undergoing male bone anchored perineal sling. J Urol (2009) 0.75
Management of urinary retention and obstruction following surgery for stress urinary incontinence. Curr Urol Rep (2002) 0.75
Urodynamic findings in women with insensible incontinence. Int J Urol (2012) 0.75
Fistulization between ectopic ureteral stump and uterus following nephroureterectomy: case report. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Vaginal granulation tissue secondary to bone anchors: experience in two patients. J Urol (2003) 0.75
Pelvic floor reconstruction: state-of-the-art and beyond. Urol Clin North Am (2004) 0.75